A Corridor company pioneering autonomous artificial intelligence (AI) in health care has unveiled a new acquisition and a new brand to reflect its growing platform of technologies designed to detect illness without the need for specialists.
The Coralville company formerly known as IDx has renamed itself Digital Diagnostics after purchasing Boston-based 3Derm Systems last month for an undisclosed amount.
With the deal, Digital Diagnostics now holds the intellectual property for two milestone autonomous AI technologies – its flagship, IDx-DR, which diagnoses diabetic retinopathy and diabetic macular edema, and 3DermSpot, a skin cancer diagnostic system that received two Breakthrough Device designations from the Food and Drug Administration in January and is currently under clinical investigation.
Dr. Michael Abramoff, who founded IDx in 2010, said the purchase and rebrand furthers the company’s goal of offering an expanding suite of AI diagnostic tools across a variety of medical specialties.
“We’re creating integrated solutions for customers, a transparent and seamless platform,” Dr. Abramoff said, adding Digital Diagnostics will continue developing plug-and-play-style AI diagnostic tools for providers. He likened the concept to downloading apps on a mobile phone: “You can just add it on, and you’re done.”